Bio-Techne Non-GAAP EPS of $0.42 beats by $0.04, revenue of $287.16M beats by $7.09M

Bio-Techne press release ( NASDAQ: TECH ): Q1 Non-GAAP EPS of $0.42 beats by $0.04 .

Revenue of $287.16M (+3.7% Y/Y) beats by $7.



09M . Continued adoption and utilization across the Diagnostics & Spatial Biology ("DSS"), formerly Diagnostics & Genomics, portfolio led to 14% organic segment growth (14% reported). Continued uptake of our cell and gene therapy workflow solutions, including strong growth in our GMP reagent offerings.

Shares +2.49% PM. More on Bio-Techne Bio-Techne Corporation (TECH) Q4 2024 Earnings Call Transcript Bio-Techne Q1 2025 Earnings Preview Bio-Techne GAAP EPS of $0.

49 beats by $0.16, revenue of $306.1M in-line Seeking Alpha’s Quant Rating on Bio-Techne Historical earnings data for Bio-Techne.